Development Of Center For Rapid Cancer Drug Discovery

癌症药物快速发现中心的发展

• 批准号: 6830570
• 负责人: RONALD B HERBERMAN
• 金额: $ 7.43万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2005-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6830570
• 关键词: antineoplastics; biomarker; biotherapeutic agent; cooperative study; drug discovery /isolation; neoplasm /cancer; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; orphan disease /drug; small molecule

DESCRIPTION (provided by applicant): We envision the development of a Center for Rapid Cancer Drug Discovery and Translational Research (CRCDDTR), anchored by two premier research organizations - The University of Pittsburgh Cancer Institute (UPCI) and Eli Lilly Oncology group in partnership with lmmunosite Inc, and the Pittsburgh Life Sciences Greenhouse (PLSG), a state-affiliated economic development agency representing more than 60 local life sciences companies. The Center will solicit proposals for relevant projects not only from within UPCI and Eli Lilly, but also from the members of PLSG. Utilizing the experience of its research anchors, UPCI, Eli Lilly and ImnunoSite, the Steering Committee of the Center will quickly identify the most promising projects. UPCI will then mobilize the appropriate multidisciplinary team from among its research and clinical translation divisions. Each team will have access to the full resources of the UPCI, including its extensive core facilities for drug discovery validation and development. In this way, the CRCDDTR will have access to a broad pipeline of new methods, targets, therapies, biomarkers and other interventions as well as the expertise, resources and funds to quickly progress toward a milestone-driven go/no go decision. By applying its limited funds in a strategic way, CRCDDTR will quickly advance the most promising candidates that our anchors and our region have to address the major unmet medical needs in the cancer market. The CRCDDTR will utilize the experience of the UPCI in the Limbach Entrepreneurial Center (LEC), a cancer-dedicated Business Development group, to assist in the development of its membership agreement, which will permit intellectual property terms to be defined specifically for each project, to accommodate variations in the origins of materials or in expected outcomes. The agreement will permit and encourage the development of relationships between its partners outside of the academic arena as appropriate. The LEC will also manage and facilitate the interactions with all partners and also continue focused educational programs to familiarize UPCI faculty with the principles and advantages of technology transfer and commercialization of research innovations.

描述(由申请人提供)： 我们设想发展一个癌症药物快速发现和转化研究中心(CRCDDTR)，由两个主要研究机构-匹兹堡大学癌症研究所(UPCI)和礼来肿瘤集团与Immunosite Inc.合作，以及匹兹堡生命科学温室(PLSG)--这是一个代表60多家当地生命科学公司的州附属经济发展机构。 该中心不仅将向UPCI和礼来公司内部征求相关项目的建议书，还将向PLSG成员征求建议书。该中心的指导委员会将利用其研究支柱UPCI、Eli Lilly和ImnunoSite的经验，迅速确定最有前景的项目。然后，UPCI将从其研究和临床翻译部门中动员适当的多学科团队。每个团队都将获得UPCI的全部资源，包括其广泛的用于药物发现、验证和开发的核心设施。 通过这种方式，CRCDDTR将有机会获得广泛的新方法、目标、疗法、生物标记物和其他干预措施，以及专业知识、资源和资金，以迅速朝着里程碑式的决定前进。 通过战略性地运用其有限的资金，CRCDDTR将迅速推动最有希望的候选人，我们的主播和我们的地区必须解决癌症市场中尚未得到满足的主要医疗需求。 CRCDDTR将利用UPCI在林巴赫创业中心(LEC)的经验来协助制定其成员协议，该协议将允许为每个项目专门定义知识产权术语，以适应材料来源或预期结果的差异。该协议将允许并鼓励其合作伙伴之间酌情发展学术领域以外的关系。LEC还将管理和促进与所有合作伙伴的互动，并继续开展重点教育项目，让UPCI的教职员工熟悉技术转让和研究创新商业化的原则和优势。